With Concentra Biosciences expanding its stock influence in Pliant Therapeutics and Acelyrin, the two biotechs have shored up their corporate defences against a potential acquisition. Both Pliant ...

Pliant is committed to the development of its other clinical and pipeline assets including PLN-101095 in oncology. The Company is currently enrolling the fourth of five planned dose cohorts in a ...

Pliant Therapeutics has discontinued a phase 2b/3 trial after recording at least a 7% higher rate of adverse events tied to idiopathic pulmonary fibrosis (IPF) in the treatment arms compared to ...

SOUTH SAN FRANCISCO - Pliant Therapeutics, Inc. (NASDAQ: PLRX), a biopharmaceutical company currently valued at $94.3 million, announced interim results from a Phase 1 clinical trial of PLN-101095 ...

Pliant Therapeutics (PLRX) announced data from the first three of five potential cohorts of its ongoing Phase 1 dose escalation clinical trial evaluating PLN-101095, an integrin alphavbeta8 and ...

Pliant Therapeutics halted its Phase 2b trial for bexotegrast in IPF, raising concerns about future prospects. Needham downgraded Pliant to Hold from Buy, citing a lack of near-term catalysts and ...

SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that its Board of Directors has unanimously adopted a limited duration ...

Pliant Therapeutics (PLRX) announced that following a prespecified data review and recommendation by the trial’s independent Data Safety Monitoring Board, as well as a secondary review and ...

Also Read: Pliant Therapeutics Drops IPF Drug Trial After Review, Analyst Flags Uncertain Future PLN-101095 was generally well tolerated across all doses tested. Nine patients with six different ...

March 17, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced data from the first three of five potential cohorts of its ongoing Phase 1 dose escalation clinical ...

Peste 18% dintre tinerii cu vârstele cuprinse între 15 și 34 de ani au consumat cel puțin o dată substanțe psihoactive interzise, cel mai folosit drog fiind canabisul, a declarat marți, la Deva, ...

ai Asociației Antidrog Est-Europene, precum și ai Administrației Spitalelor și Serviciilor Medicale din București. AGERPRES/(A - redactor: Livia Popescu, editor: Claudia Stănescu, editor online: ...